Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/BMu1e2fpcZE/3Rkz
Saturday, February 19, 2011
Micell Technologies Enrolls First Patient In CE Mark DESSOLVE II Study Of MiStent? Drug-Eluting Coronary Stent (DES)
Micell Technologies,? Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent? Drug-Eluting Coronary Stent System (MiStent DES)...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment